• Enorama Pharma secured a USD 2.5 million loan from controlling shareholder DS Global, maturing Dec. 31, 2027.
• The new agreement and an earlier amendment restore equity above registered share capital, as DS Global loans qualify for equity classification.
• DS Global can demand repayment only through conversion into shares.
• The loan is interest-free; a proposed 9% annual rate requires shareholder approval and would apply from the meeting date.
• Optional repayment through a share issue would use SEK 0.4 per share and an exchange rate of SEK 10 per USD 1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enorama Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202611131000BITN____UKPR__SV_20261113-BIT-8972-0) on November 13, 2026, and is solely responsible for the information contained therein.